1. Generics Bulletin
  2. >>Business
  3. >>Manufacturing

US FDA Scrutinizes Process Risks After Nitrosamines Found In ARBs

 
• By Bowman Cox

There is a new focus in reviews and inspections where nitrosamines or other dangerous process-related impurities might form.

FDABldg1ExteriorWithCircle_1200x675
agency grows more cautious about impurities

The US Food and Drug Administration is paying more attention to process-related impurities now that process-related potential carcinogens have been found in certain blood pressure and heart failure medications, says Janet Woodcock, director of the agency’s Center for Drug Evaluation and Research.

Even as the agency clamps down on the impurities, called nitrosamines, Woodcock emphasized in a 28 August 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.